Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 20, 2017
What is the competitive landscape for GLAXOSMITHKLINE LLC, and what generic alternatives to GLAXOSMITHKLINE LLC drugs are available?
GLAXOSMITHKLINE LLC has fifteen approved drugs.| Patents: | 8 |
| Tradenames: | 14 |
| Ingredients: | 9 |
| NDAs: | 15 |
| Drug Master File Entries: (click here to view) | 15 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
lamotrigine | Extended-release Tablets | 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg | LAMICTAL XR | 2/12/2014 |
lamotrigine | Orally Disintegrating Tablets | 25 mg, 50 mg, 100 mg, and 200 mg | LAMICTAL ODT | 12/21/2009 |
atovaquone | Oral Suspension | 750 mg/5 mL | MEPRON | 10/20/2009 |
ropinirole hydrochloride | Extended-release Tablets | 6 mg | REQUIP XL | 7/22/2009 |
ropinirole hydrochloride | Extended-release Tablets | 12 mg | REQUIP XL | 2/5/2009 |
ropinirole hydrochloride* | Extended-release Tablets | 3 mg | REQUIP XL | 1/8/2009 |
ropinirole hydrochloride | Extended-release Tablets | 3 mg | REQUIP XL | 1/8/2009 |
ropinirole hydrochloride | Extended-release Tablets | 8 mg | REQUIP XL | 11/3/2008 |
ropinirole hydrochloride | Extended-release Tablets | 4 mg | REQUIP XL | 10/31/2008 |
ropinirole hydrochloride | Extended-release Tablets | 2 mg | REQUIP XL | 10/14/2008 |
propafenone | Extended-release Capsules | 325 mg | RYTHMOL SR | 11/7/2006 |
propafenone hydrochloride | Extended-release Capsules | 225 mg and 425 mg | RYTHMOL SR | 10/11/2006 |
ropinirole hydrochloride | Tablets | 3 mg, 4 mg and 5 mg | REQUIP | 2/4/2005 |
ropinirole hydrochloride | Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | REQUIP | 12/22/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,647,656 | Orally disintegrating tablet compositions of lamotrigine | ► Subscribe | |||||||||||||||||||||||||||
| 8,460,706 | Hydrophilic/lipophilic polymeric matrix dosage formulation | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eurasian Patent Organization | 008286 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1524981 | ► Subscribe | |||||||||||||||||||||||||||
| Peru | 08002003 | ► Subscribe | |||||||||||||||||||||||||||
| Brazil | 0307319 | ► Subscribe | |||||||||||||||||||||||||||
| Russian Federation | 2005105353 | ► Subscribe | |||||||||||||||||||||||||||
| China | 1655768 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | I342213 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1474114 | ► Subscribe | |||||||||||||||||||||||||||
| Colombia | 5680405 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5346021 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0009 | Belgium | ► Subscribe | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 | ||||||||||||||||||||||||||
| 2011 00026 | Denmark | ► Subscribe | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 | ||||||||||||||||||||||||||
| C/GB99/008 | United Kingdom | ► Subscribe | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 | ||||||||||||||||||||||||||
| C0030 | France | ► Subscribe | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 | ||||||||||||||||||||||||||
| /1997 | Austria | ► Subscribe | PRODUCT NAME: ''NARATRIPTAN'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATES EINSCHLIESSLICH DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-22059 19970731; FIRST REGISTRATION: SE 13382 19970310 | ||||||||||||||||||||||||||
| C0036 | Belgium | ► Subscribe | PRODUCT NAME: CHLORHYDRATE DE ROPINIROLE (=ROPINIROLE); NAT. REGISTRATION NO/DATE: 981 IS 120 F 3 19970414; FIRST REGISTRATION: GB PL 10592/0085 19960702 | ||||||||||||||||||||||||||
| 70035 | Netherlands | ► Subscribe | PRODUCT NAME: NARATRIPTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAA RDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER NARATRIPTAN-HYDROCHLOR IDE; NAT. REGISTRATION NO/DATE: RVG 21444 19970801; FIRST REGISTRATION: SE 13382 19970310 | ||||||||||||||||||||||||||
| C0102 | Belgium | ► Subscribe | PRODUCT NAME: NARATRIPTAN HYDROCHLORIDUM; REGISTRATION NO/DATE: 725 IS 278 F 3 19970818; FIRST REGISTRATION: SE 13382 19970310 | ||||||||||||||||||||||||||
| 0443983/03 | Switzerland | ► Subscribe | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 | ||||||||||||||||||||||||||
| C/GB02/037 | United Kingdom | ► Subscribe | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,676 others who get our Drug Patent Expiration Alerts:
